FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.
P/E ratio for FDC Limited (FDC.NS)
P/E ratio as of 2023: 23.35
According to FDC Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.35. At the end of 2022 the company had a P/E ratio of 21.96.
P/E ratio history for FDC Limited from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 23.35 |
| 2022 | 21.96 |
| 2021 | 20.06 |
| 2020 | 16.13 |
| 2019 | 13.98 |
| 2018 | 16.97 |
| 2017 | 26.40 |
| 2016 | 19.23 |
| 2015 | 21.03 |
| 2014 | 18.27 |
| 2013 | 16.65 |
| 2012 | 10.83 |
| 2011 | 10.74 |
| 2010 | 12.58 |
| 2009 | 10.08 |
| 2008 | 7.59 |
| 2007 | 8.56 |
| 2006 | 9.10 |
| 2005 | 13.43 |
| 2004 | 15.84 |